AbbVie ( ABBV 0.64%) is a leader in biopharmaceuticals with a product portfolio spanning multiple therapeutic areas, ...

Aurion Biotech, Inc. plans $100M IPO for corneal disease treatments, limited competition, Phase 1/2 trials underway with ...

Biotech investing can be tricky. Often, the drugs that these fledgling companies produce don’t pan out, and shareholders take ...

News of the layoffs come just one day after the company reported a 5% year over year revenue increase — boosting revenue to ...

With the Canadian economy experiencing a contraction in November and a recent interest rate cut by the Bank of Canada due to tariff uncertainties, investors are navigating a complex landscape. In such ...

Relmada, which has turned to strategic options after scrapping two phase 3 trials in major depressive disorder (MDD), is ...

PDS Biotechnology (PDSB) reaffirmed the Company’s guidance of initiating its VERSATILE-003 Phase 3 clinical trial of Versamune HPV plus ...

A Huntsville-based biotechnology company has secured $10 million in funding to begin the trial of a new way to deliver medication to advanced Parkinson’s disease patients.

From Chinese social media reeling about Covid to rail contracts in East Africa, here’s a round-up from today’s China and ...

The BioSecure Act seeks to reduce US-China biotech ties, creating potential for India to become a biomanufacturing hub.

Let us look at some biotech stocks, AMGN, CRSP, MRNA, SRPT and VRTX, which are poised to beat on fourth-quarter earnings.

Swiss biotech Bioversys AG shares started trading at 36.5 Swiss francs ($40.29) on the SIX Swiss Exchange on Friday, slightly up from the final price for its initial public offering (IPO) of 36 Swiss ...